Occam Places Dan Marquess as CSO at Vicinitas Therapeutics
Occam’s commitment to help meaningfully shape and build structure in high science platform companies has yielded another impressive result in the placement of Dan Marquess as CSO at Vicinitas, Dan Nomura’s latest creation that seeks to commercialize a compellingly novel approach to drugging the “undruggable.”
With $65M in the bank from Deerfield and a16z and with Marquess leading the scientific charge, Vicinitas is well positioned to deliver on the platform’s formidable potential around leveraging protein stabilization to develop a novel class of therapeutics.
Prior to Vicinitas, Marquess was the CSO at UNITY Biotechnology and prior to that role had spent more than 15 years at Theravance.
Dan earned his D.Phil in Chemistry from Oxford University and his undergraduate degree in Chemistry from Queens University.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.